Fuso Pharmaceutical Industries,Ltd.

Tokyo Stock Exchange 4538.T

Fuso Pharmaceutical Industries,Ltd. EBITDA Margin for the year ending March 31, 2024: 6.62%

Fuso Pharmaceutical Industries,Ltd. EBITDA Margin is 6.62% for the year ending March 31, 2024, a -27.03% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.

Fuso Pharmaceutical Industries,Ltd. EBITDA Margin for the year ending March 31, 2023 was 9.08%, a 0.82% change year over year.
Fuso Pharmaceutical Industries,Ltd. EBITDA Margin for the year ending March 31, 2022 was 9.00%, a -7.51% change year over year.
Fuso Pharmaceutical Industries,Ltd. EBITDA Margin for the year ending March 31, 2021 was 9.74%, a 32.27% change year over year.
Fuso Pharmaceutical Industries,Ltd. EBITDA Margin for the year ending March 31, 2020 was 7.36%, a -1.68% change year over year.

Key data

Date	EBITDA Margin	EBIT Margin	Depreciation and Amortization	EBIT

Tokyo Stock Exchange: 4538.T

Fuso Pharmaceutical Industries,Ltd.

CEO	Mr. Mikio Toda
IPO Date	Jan. 1, 2001
Location	Japan
Headquarters	1-7-10, Doshomachi
Employees	1,370
Sector	Consumers Staples
Industries Cleaning Supplies Automotive Parts Composite Materials Hardware & Electronics Non-Alcoholic Beverages Personal Care Pharmaceuticals Plastics

Description

Fuso Pharmaceutical Industries,Ltd. manufactures and sells pharmaceutical products in Japan. The company offers ethical drugs, such as injectables and artificial kidney dialysates; and medical machinery and equipment. It also rents real estate properties. The company was founded in 1937 and is headquartered in Osaka, Japan.

Key trends

Past 5 years